The ATS/ERS 2025 statement on interstitial pneumonia classification updates the 2013 statement, with insights on secondary ...

Nalbuphine is a mixed opioid agonist/antagonist that blocks the mu opioid receptor and activates the kappa opioid receptor, ...

Early management of obstructive sleep apnea in patients with IPF could slow disease progression and improve outcomes.

Quantitative CT metrics can be used to define progressive pulmonary fibrosis and have prognostic value in patients with ...

Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ...

IPF-associated cough affects up to 80% of patients with IPF, substantially impairing their quality of life; consequently, ...

With the “gym,” Insilico is now targeting other biotech and pharmaceutical companies, offering to train new AI models for ...

BMY spotlights a deep pipeline with multi-billion-dollar potential, key late-stage data readouts ahead, and encouraging ...

Among patients with idiopathic pulmonary fibrosis, the risk for all-cause mortality was significantly lower with vs. without ...

A Co Antrim woman who is waiting for a double lung transplant has shared her story to raise awareness of chest conditions and to encourage others facing similar battles.

Minna Purokivi was appointed as Professor of Respiratory Medicine at the University of Eastern Finland this January. Her research group focuses, in particular, on interstitial lung diseases (ILD), ...

Learn to manage chronic fatigue from IPF with exercise, nutrition, sleep hygiene, and energy-saving strategies.